Dimitra Stafylaki

Dimitra Stafylaki

Auto-generated profile, based on publicly available information

Dimitra Stafylaki

Department of Clinical Microbiology and Microbial Pathogenesis, University Hospital of Heraklion, Crete, Greece

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Infection & Chemotherapy
Verified
Journal Article
Open access
SMSofia Maraki
Sofia Maraki
VMViktoria Eirini Mavromanolaki
Viktoria Eirini Mavromanolaki
DSDimitra Stafylaki
Dimitra Stafylaki
EIEvangelia Iliaki-Giannakoudaki
Evangelia Iliaki-Giannakoudaki
AKAnna Kasimati
Anna Kasimati
GHGeorge Hamilos
George Hamilos
Maraki S, et al. Infect Chemother. 2024 Jan;56:e2. https://doi.org/10.3947/ic.2023.0098

1 February 2017 in Anaerobe
Verified
Journal Article
Closed access
SMSofia Maraki
Sofia Maraki
GEGeorge Evangelou
George Evangelou
DSDimitra Stafylaki
Dimitra Stafylaki
ESEfstathia Scoulica
Efstathia Scoulica

1 January 2018 in Infection & Chemotherapy
Verified
Journal Article
Open access
PDF file
SMSofia Maraki
Sofia Maraki
VMViktoria Eirini Mavromanolaki
Viktoria Eirini Mavromanolaki
DSDimitra Stafylaki
Dimitra Stafylaki
GHGeorge Hamilos
George Hamilos
GSGeorge Samonis
George Samonis
Maraki S, et al. Infect Chemother. 2018 Dec;50(4):328-339. https://doi.org/10.3947/ic.2018.50.4.328

1 January 2024 in Infection & Chemotherapy
Verified
Journal Article
Open access
SMSofia Maraki
Sofia Maraki
VMViktoria Eirini Mavromanolaki
Viktoria Eirini Mavromanolaki
AKAnna Kasimati
Anna Kasimati
EIEvangelia Iliaki-Giannakoudaki
Evangelia Iliaki-Giannakoudaki
DSDimitra Stafylaki
Dimitra Stafylaki
Maraki S, et al. Infect Chemother. 2024 Oct;56:e53. https://doi.org/10.3947/ic.2024.0060

27 January 2023 in Journal of Chemotherapy
Verified
Journal Article
Closed access
SMSofia Maraki
Sofia Maraki
VMViktoria Eirini Mavromanolaki
Viktoria Eirini Mavromanolaki
DSDimitra Stafylaki
Dimitra Stafylaki
ESEffie Scoulica
Effie Scoulica
Infections by carbapenem-resistant Klebsiella pneumoniae (CRKP) remain one of the greatest healthcare threats associated with significant morbidity and mortality. New antimicrobials were recently developed to address this threat. We assessed the epidemiology of carbapenemase-producing K. pneumoniae (CPKP) isolates recovered in a Greek university hospital during 2021, and their susceptibilities to old and newer antimicrobials. Minimum inhibitory concentrations (MICs) were determined by the MIC Test Strip method, except for cefiderocol (CFDC) and colistin that were evaluated by the broth microdilution method. A total of 110 CPKP strains were isolated, with KPC-producers being the most prevalent (64.6%). Among the agents tested, plazomicin (PL) displayed the highest activity against all the isolates (MIC50/MIC90, 0.5/1.5 μg/ml), followed by tigecycline (MIC50/MIC90, 1.5/4 μg/ml). All KPC-producing K. pneumoniae were susceptible to ceftazidime-avibactam (CAZ/AVI) and meropenem-vaborbactam (M/V) and 97.2% of them to imipenem-relebactam (I/R). Among the MBL-producing isolates, PL and CFDC exhibited the highest activity.